KEYNOTE-042.

Headline: If you guessed wrong on this one, Merck’s marketing dollars aren’t working as well as they should be. Bottom line: Results of this trial demonstrate that patients with non-small cell lung cancer without EGFR or ALK aberrations and as little as 1% PD-L1 expression randomized to upfront pembrolizumab alone had better overall survival than those receiving platinum-based chemo. | Lopes, ASCO 2018